Found: 14
Select item for more details and to access through your institution.
Melanoma and Vitiligo: In Good Company.
- Published in:
- International Journal of Molecular Sciences, 2019, v. 20, n. 22, p. 5731, doi. 10.3390/ijms20225731
- By:
- Publication type:
- Article
Differences in individual and environmental factors between cutaneous melanoma and atypical Spitz tumour in children and adolescents.
- Published in:
- European Journal of Pediatrics, 2022, v. 181, n. 1, p. 263, doi. 10.1007/s00431-021-04204-x
- By:
- Publication type:
- Article
Correction to: Differences in individual and environmental factors between cutaneous melanoma and atypical Spitz tumour in children and adolescents.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Diagnosis and categorization of acral melanocytic lesions using teledermoscopy.
- Published in:
- Journal of Telemedicine & Telecare, 2004, v. 10, n. 6, p. 346, doi. 10.1258/1357633042602017
- By:
- Publication type:
- Article
Effectiveness of risankizumab for the treatment of psoriatic arthritis: a multicenter, real‐world study.
- Published in:
- International Journal of Dermatology, 2024, v. 63, n. 10, p. 1383, doi. 10.1111/ijd.17156
- By:
- Publication type:
- Article
Scleredema of Buschke with prominent periorbital edema.
- Published in:
- International Journal of Dermatology, 2017, v. 56, n. 10, p. e193, doi. 10.1111/ijd.13639
- By:
- Publication type:
- Article
Interleukin (IL)-17/IL-36 axis participates to the crosstalk between endothelial cells and keratinocytes during inflammatory skin responses.
- Published in:
- PLoS ONE, 2020, v. 15, n. 4, p. 1, doi. 10.1371/journal.pone.0222969
- By:
- Publication type:
- Article
Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study.
- Published in:
- Acta Dermato-Venereologica, 2021, v. 101, n. 10, p. 1, doi. 10.2340/00015555-3816
- By:
- Publication type:
- Article
Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study.
- Published in:
- Acta Dermato-Venereologica, 2021, v. 101, n. 3, p. 1, doi. 10.2340/00015555-3712
- By:
- Publication type:
- Article
2-Year Experience with Risankizumab in the Treatment of Plaque Psoriasis in Lazio Region, Italy.
- Published in:
- Dermatologic Therapy, 2023, p. 1, doi. 10.1155/2023/9832296
- By:
- Publication type:
- Article
Risankizumab for the treatment of moderate‐to‐severe psoriasis: A multicenter, retrospective, 1 year real‐life study.
- Published in:
- Dermatologic Therapy, 2022, v. 35, n. 6, p. 1, doi. 10.1111/dth.15489
- By:
- Publication type:
- Article
Tildrakizumab in moderate‐to‐severe plaque psoriasis: A multicenter, retrospective, real‐life study.
- Published in:
- Dermatologic Therapy, 2022, v. 35, n. 6, p. 1, doi. 10.1111/dth.15488
- By:
- Publication type:
- Article
IL-38 has an anti-inflammatory action in psoriasis and its expression correlates with disease severity and therapeutic response to anti-IL-17A treatment.
- Published in:
- Cell Death & Disease, 2018, v. 9, n. 11, p. 1, doi. 10.1038/s41419-018-1143-3
- By:
- Publication type:
- Article
Paradoxical psoriasis induced by TNF‐α blockade shows immunological features typical of the early phase of psoriasis development.
- Published in:
- Journal of Pathology: Clinical Research, 2020, v. 6, n. 1, p. 55, doi. 10.1002/cjp2.147
- By:
- Publication type:
- Article